Action Theratechnologies - TH

Votre Hub pour des idées et discussions en direct en temps réel

Premium

Dernier

3,65

Prix Achat

3,52

Prix Vente

3,78

Volume échangé

38 475

3,51 Fourchette du Jour 3,68

1,59 Plage de 52 semaines 4,33

Clôture Veille

3,60

Ouverture

3,55

Dernière Transaction

3.65

Dernière heure de transaction

Volume moyen (3 m)

133 325

Volume financier

VWAP

Theratechnologies Presents Novel Data at ACTHIV 2025 Underscoring Importance of Managing Excess Visceral Abdominal Fat (EVAF) in People with HIV

VAMOS analysis highlights link between EVAF and reduced muscle quality Case series reports success with...

Theratechnologies Provides Update on Sale Process

MONTREAL, April 15, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”...

Theratechnologies Responds to Future Pak’s Press Release and Announces Exclusive Discussions with Another Potential Acquiror for the Sale of the Company

MONTREAL, April 11, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”...

Theratechnologies Reports Financial Results for the First Quarter 2025 and Reviews Key Achievements

FDA Approves EGRIFTA WR™ (Tesamorelin F8) to Treat Excess Visceral Abdominal Fat in Adults with HIV and...

Theratechnologies Receives FDA Approval of Prior Approval Supplement (PAS) for EGRIFTA SV® sBLA

FDA action allows for unrestricted distribution of EGRIFTA SV®, removing uncertainty with respect to all...

Theratechnologies to Announce First Quarter 2025 Financial Results and Provide Business Update

MONTREAL, April 03, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”...

Theratechnologies Receives FDA Approval for EGRIFTA WR™ (Tesamorelin F8) to Treat Excess Visceral Abdominal Fat in Adults with HIV and Lipodystrophy

New, improved formulation set to replace EGRIFTA SV® MONTREAL, March 25, 2025 (GLOBE NEWSWIRE...

Theratechnologies Presents Encouraging Virologic Suppression Data from the PROMISE-US Trial of Ibalizumab at CROI

Results show similar levels of virus undetectability in patients on ibalizumab-containing regimens as in...

Theratechnologies Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2024

Achieved record positive Adjusted EBITDA* of $20 million for FY2024 (net loss of $8.3 million), exceeding...

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0.03	0.828729281768	3.62	3.69	3.51	34887	3.59309155	CS
4	-0.19	-4.94791666667	3.84	4.1	3.48	67791	3.79997459	CS
12	1.34	58.0086580087	2.31	4.33	1.76	133325	3.1104216	CS
26	1.98	118.562874251	1.67	4.33	1.6	94066	2.87276806	CS
52	1.86	103.910614525	1.79	4.33	1.59	60250	2.62257614	CS
156	-7.95	-68.5344827586	11.6	15	1.22	46540	3.31916622	CS
260	-8.07	-68.8566552901	11.72	22.4	1.22	63790	9.32811391	CS

TH - Frequently Asked Questions (FAQ)

What is the current Theratechnologies share price?

The current share price of Theratechnologies is $ 3,65

What is the 1 year trading range for Theratechnologies share price?

Theratechnologies has traded in the range of $ 1,59 to $ 4,33 during the past year

Volume
% Gagnants
% Perdants

Symbole	Prix	Vol.
AGRI.UAgrinam Acquisition Corporation	US$ 16,00 (17 677,78%)	2k
BABYElse Nutrition Holdings Inc	$ 0,015 (50,00%)	735,56k
IVQ.UInvesque Inc	US$ 0,11 (22,22%)	123k
UREUr Energy Inc	$ 1,20 (21,21%)	517,25k
GENMGeneration Mining Limited	$ 0,32 (20,75%)	1,48M
GMTNGold Mountain Mining Corp	$ 0,01 (-33,33%)	1,74M
VRTSVertiqal Studios Corporation	$ 0,015 (-25,00%)	4,31k
XMF.AM Split Corp	$ 0,49 (-20,97%)	1 000
PPRPrairie Provident Resources Inc	$ 0,03 (-14,29%)	24,48k
TPX.AMolson Coors Canada Inc	$ 79,00 (-11,24%)	288
WCPWhitecap Resources Inc	$ 8,74 (2,94%)	9,55M
TDToronto Dominion Bank	$ 92,93 (0,13%)	7,65M
ENBEnbridge Inc	$ 63,22 (0,89%)	7,02M
TLOTalon Metals Corp	$ 0,20 (17,65%)	6,99M
CVECenovus Energy Inc	$ 18,72 (1,19%)	6,7M

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Theratechnologies Inc (TH)

Votre Hub pour des idées et discussions en direct en temps réel

Statistiques et détails clés

TH Dernières nouvelles

Theratechnologies Presents Novel Data at ACTHIV 2025 Underscoring Importance of Managing Excess Visceral Abdominal Fat (EVAF) in People with HIV

Theratechnologies Provides Update on Sale Process

Theratechnologies Responds to Future Pak’s Press Release and Announces Exclusive Discussions with Another Potential Acquiror for the Sale of the Company

Theratechnologies Reports Financial Results for the First Quarter 2025 and Reviews Key Achievements

Theratechnologies Receives FDA Approval of Prior Approval Supplement (PAS) for EGRIFTA SV® sBLA

Theratechnologies to Announce First Quarter 2025 Financial Results and Provide Business Update

Theratechnologies Receives FDA Approval for EGRIFTA WR™ (Tesamorelin F8) to Treat Excess Visceral Abdominal Fat in Adults with HIV and Lipodystrophy

Theratechnologies Presents Encouraging Virologic Suppression Data from the PROMISE-US Trial of Ibalizumab at CROI

Theratechnologies Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2024

Theratechnologies Presents Novel Data at ACTHIV 2025 Underscoring Importance of Managing Excess Visceral Abdominal Fat (EVAF) in People with HIV

Theratechnologies Provides Update on Sale Process

Theratechnologies Responds to Future Pak’s Press Release and Announces Exclusive Discussions with Another Potential Acquiror for the Sale of the Company

Theratechnologies Reports Financial Results for the First Quarter 2025 and Reviews Key Achievements

Theratechnologies Receives FDA Approval of Prior Approval Supplement (PAS) for EGRIFTA SV® sBLA

Theratechnologies to Announce First Quarter 2025 Financial Results and Provide Business Update

Theratechnologies Receives FDA Approval for EGRIFTA WR™ (Tesamorelin F8) to Treat Excess Visceral Abdominal Fat in Adults with HIV and Lipodystrophy

Theratechnologies Presents Encouraging Virologic Suppression Data from the PROMISE-US Trial of Ibalizumab at CROI

TH - Frequently Asked Questions (FAQ)

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Theratechnologies Inc (TH) Cours

Theratechnologies Inc (TH)

Votre Hub pour des idées et discussions en direct en temps réel

Statistiques et détails clés

TH Dernières nouvelles

Theratechnologies Presents Novel Data at ACTHIV 2025 Underscoring Importance of Managing Excess Visceral Abdominal Fat (EVAF) in People with HIV

Theratechnologies Provides Update on Sale Process

Theratechnologies Responds to Future Pak’s Press Release and Announces Exclusive Discussions with Another Potential Acquiror for the Sale of the Company

Theratechnologies Reports Financial Results for the First Quarter 2025 and Reviews Key Achievements

Theratechnologies Receives FDA Approval of Prior Approval Supplement (PAS) for EGRIFTA SV® sBLA

Theratechnologies to Announce First Quarter 2025 Financial Results and Provide Business Update

Theratechnologies Receives FDA Approval for EGRIFTA WR™ (Tesamorelin F8) to Treat Excess Visceral Abdominal Fat in Adults with HIV and Lipodystrophy

Theratechnologies Presents Encouraging Virologic Suppression Data from the PROMISE-US Trial of Ibalizumab at CROI

Theratechnologies Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2024

Theratechnologies Presents Novel Data at ACTHIV 2025 Underscoring Importance of Managing Excess Visceral Abdominal Fat (EVAF) in People with HIV

Theratechnologies Provides Update on Sale Process

Theratechnologies Responds to Future Pak’s Press Release and Announces Exclusive Discussions with Another Potential Acquiror for the Sale of the Company

Theratechnologies Reports Financial Results for the First Quarter 2025 and Reviews Key Achievements

Theratechnologies Receives FDA Approval of Prior Approval Supplement (PAS) for EGRIFTA SV® sBLA

Theratechnologies to Announce First Quarter 2025 Financial Results and Provide Business Update

Theratechnologies Receives FDA Approval for EGRIFTA WR™ (Tesamorelin F8) to Treat Excess Visceral Abdominal Fat in Adults with HIV and Lipodystrophy

Theratechnologies Presents Encouraging Virologic Suppression Data from the PROMISE-US Trial of Ibalizumab at CROI

TH - Frequently Asked Questions (FAQ)

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Connectez-vous

Supprimer les publicités